• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques

Jul 19, 2023 | HIV

A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival

Jul 10, 2023 | Breast Cancer

Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient

Jul 7, 2023 | Uncategorized

Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

Jul 7, 2023 | Uncategorized

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

Oct 4, 2020 | Merkel Cell Carcinoma

« Older Entries
Next Entries »

Recent Posts

  • LUGPA Regional Meeting
  • ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
  • ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
  • Jefferies Global Healthcare Conference 2025
  • ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShieldTM Platform in the Middle East
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap